Global News Wire: Pluristem Therapeutics Forms Strategic Alliance with ChaBio & Diostech
Pluristem Therapeutics (PSTI) is a developer of placenta-based cell therapies. They have just formed a strategic alliance with Cha Bio&Diostech.
pluristem therapeutics
BREAKING: Pluristem Announces Pricing of Public Offering
Pluristem Therapeutics Inc. announced that it has priced a firm commitment underwritten public offering of 8,000,000 units, with each unit consisting of one share of the company’s common stock and one warrant to purchase 0.35 of a share of the company’s common stock, at a purchase price of $4.00 per unit for an aggregate gross offering amount of $32 million. The offering is expected to close on or about September 19, 2012, subject to customary closing conditions.
PAD Awareness Month Brings Often-Overlooked Cardiovascular Disease to the Forefront
While most people are familiar with the big-name heart problems such as cardiac arrest and congestive heart failure, PAD is often overlooked.